Ua kūleʻa ʻo Lymphoma Australia i ka loaʻa ʻana o kahi haʻawina honua mai AbbVie e alakaʻi i nā nīnauele me nā poʻe loea o Australia a me ka honua ma lymphoma a me ka maʻi maʻi lymphocytic maʻi (CLL). E hōʻike ana nā nīnauele i ka ʻike hou loa e pili ana i nā hoʻokolohua lapaʻau lymphoma/CLL a me nā haʻawina mai nā wahi a puni o ka honua a hōʻike ʻia i ka wā o ka hālāwai ASH. E māhele ʻia kēia mau nīnauele a puni ka honua ma o nā hui kākoʻo hoʻomanawanui.
Ua mālama ʻo Lymphoma Australia ma kahi o 40 mau nīnauele i loko o nā lā 4 o ka hālāwai a makemake mākou e hāʻawi i ka mahalo nui iā ʻoe mai ke kaiāulu lymphoma / CLL i nā poʻe a pau i hāʻawi i ko lākou manawa, ʻike a me kā mākou akamai.
ʻO B-cell Lymphoma
Kauka Laurie Sehn - ASH Lymphoma Updates.
ʻO Dr Laurie Sehn mai British Columbia Cancer Center mai Vancouver, Kanada ka luna o ka papa aʻoaʻo olakino no ka International Lymphoma Coalition. Ua kūkākūkā ʻo Dr Sehn i kekahi o nā mea koʻikoʻi i nā lāʻau lapaʻau hou i hōʻike ʻia i ka wā o ka hālāwai ASH no lymphoma. Ua komo pū kēia me Polatuzumab (antibody drug conjugate) no ka diffuse large B-cell lymphoma (DLBCL) a me Mosunetuzumab - (bispecific antibody) i hoʻohana ʻia no nā lymphomas non-Hodgkin cell B.ʻO Kauka Chan Cheah - Ke aʻo ʻana i ka Phase I TG-1701 Relapsed a i ʻole Refractory B-cell Lymphoma.
Ua kūkākūkā ʻo A/Prof Chan Cheah, Luna Hoʻonaʻauao Haematologist, Sir Charles Gairdner Hospital, Hollywood Private Hospital & Blood Cancer Research WA, ma Perth, Western Australia, i kahi hōʻike hoʻolaha ma ASH o kahi hoʻokolokolo i mālama ʻia ma Australia me ka hoʻohana ʻana i kahi hanauna hou ʻo Bruton's Tyrosine Kinase (BTK) i kapa ʻia ʻo TG-1701 i hoʻohana ʻia i nā poʻe maʻi me nā maʻi ʻino B-cell relapsed/refractor. Hāʻawi ʻia kēia lāʻau lapaʻau waha ma ke ʻano he mea hoʻokahi i hui pū ʻia me umbralisib (PI3K inhibitor) a me ubiltuximab (glycoengineered anti-CD20 monoclonal antibody).Ua hahai ʻo Dr George - Lymphoma Updates.
ʻO Dr George Follows ka Lymphoma/CLL Clinical Lead no Cambridge a paʻa pū ʻo ia i kekahi mau koho me ka noho o ka UK CLL forum. Ua kūkākūkā ʻo Dr Follows i nā mea hou no ka lymphoma i hōʻike ʻia ma ka hālāwai ASH o ka hoihoi. Ua komo kēia i ka hoʻāʻo ʻana o ka pae I me ka hoʻohana ʻana i kahi lāʻau lapaʻau hou i kapa ʻia ʻo Monunetuzumab he antibody monoclonal bispecific e kuhikuhi ana i ka CD3 a me CD20 a ua alakaʻi i nā pane lōʻihi i nā poʻe maʻi me ka relapsed a refractory B-cell non-Hodgkin lymphoma, me nā maʻi i hoʻi hou mai CAR T -hoʻomaʻamaʻa cell.
ʻO Kauka Stephen Schuste - Hoʻoulu ʻo Mosunetuzumab i nā kala piha piha i nā maʻi me ka lymphoma non-Hodgkin B-cell.
ʻO ka bispecific monoclonal antibody Mosunetuzumab, ka mea e kuhikuhi ana i ka CD3 a me CD20, ua alakaʻi i nā pane lōʻihi i nā maʻi me B-cell non-Hodgkin lymphoma (NHL), ʻoiai i ka poʻe i loaʻa i ka maʻi i hoʻihoʻi ʻia a i ʻole refractory i ka chimeric antigen receptor (CAR) T- lāʻau lapaʻau. Kūkākūkā ʻo Dr Schuste i ke aʻo ʻana I/Ib (GO29781; NCT02500407) o mosunetuzumab i nā poʻe maʻi me B-cell non-Hodgkin lymphoma (NHL), ka poʻe i hoʻihoʻi hou / refractory (R/R) i nā lāʻau lapaʻau CAR-T a no lākou ʻO ka hoʻopaneʻe ʻana i ka lāʻau lapaʻau maikaʻi e kāpae i kēia ala. Kākoʻo ka ʻikepili mua e loaʻa i ka mosunetuzumab ka hoʻomanawanui a me ka maikaʻi paʻa i loko o ka R/R B-cell NHL i mālama mua ʻia.
ʻO Dr John Leonard - nā mea koʻikoʻi mai ka hālāwai no lymphoma.
Ua kūkākūkā ʻo Dr Leonard i kāna mau manaʻo loea mai nā hōʻike lymphoma i ka wā o ka hālāwai. Ua kūkākūkā ʻo ia i kekahi mau kumuhana e pili ana: • Follicular lymphoma - chemo free regimens • Diffuse Large B-cell Lymphoma - olakino iwi ma hope o ka R-CHOP a me CAR T-cell therapy • Mantle Cell Lymphoma - nā lāʻau hou i hui pū ʻia me ka chemotherapy • Hoʻāʻo koko DNA • Nā lāʻau lapaʻau Lymphoma
Leukemia Lymphocytic Mau Loa (CLL) & Leukemia Lymphocytic Li'ili'i (SLL)
ʻO Dr Brian Koffman - nā hoʻolaha CLL a me ke kākoʻo hoʻomanawanui.
ʻO Kauka Koffman, he kauka kaulana, kumu aʻo a me ke kauka lapaʻau i huli i ka maʻi CLL, ua hoʻolaʻa ʻo ia iā ia iho i ke aʻo ʻana a me ke kōkua ʻana i ke kaiāulu CLL mai kona hōʻoia ʻana i ka makahiki 2005. Manaʻo ʻo Kauka Koffman ʻo kāna kūlana ʻelua ma ke ʻano he kauka a me ka mea maʻi e hāʻawi i kahi ʻokoʻa. ʻike a me ka ʻike e hiki ai iā ia ke hāʻawi i nā wehewehe maopopo o nā pilikia paʻakikī a e kākoʻo i kona mau hoa maʻi a hoʻomaopopo i kona mau hoa mālama ola. He mea koʻikoʻi kēia i ka nānā ʻana i ka hoʻololi wikiwiki ʻana o ka ʻāina lapaʻau. ʻO Dr Koffman ka mea nāna i hoʻokumu i ka CLL Society, USA. Ua kūkākūkā ʻo Dr Koffman i nā mea hou CLL mai ka hālāwai kūkā me nā mea hou e pili ana i ka CAR T-cell therapy, ibrutinib, acalabrutinib, sequencing o nā lāʻau a me nā ʻano hui like ʻole. Ua kūkākūkā pū ʻo ia i ka hoʻokele maikaʻi ʻana o CLL, me ka hoʻāʻo genetic ma mua o ka mālama ʻana a me kēlā poʻe maʻi me ka maʻi unmutated, 17p del ʻaʻole pono e loaʻa i ka chemotherapy, akā i ka lāʻau lapaʻau.
ʻO Prof John Gribben lāua ʻo Deborah Sims - Ka ʻike o ka mālama ʻana iā CLL.
Ua kūkākūkā ʻo Prof Gribben i kona manaʻo i nā mea hou mai ka hālāwai kahi i hoʻoikaika ʻia ai ka nui o nā hōʻike ʻana he maikaʻi nā lāʻau lapaʻau e hoʻohana ʻia ana no ka mea ua lōʻihi ka hahai ʻana. Me ka hahai lōʻihi, hiki mai ka ʻike o nā mea ʻawaʻawa hou e ʻike ʻia. A laila hiki iā mākou ke aʻo maikaʻi i nā maʻi me ka loaʻa ʻana o ka manaʻo maikaʻi aʻe o ka mea e manaʻo ai. Ua kūkākūkā pū ʻo ia i nā lāʻau lapaʻau hou o ka hanauna hou i hoʻolauna ʻia, ʻaʻole wale ma CLL, akā nā lymphoma ʻē aʻe e like me Follicular lymphoma & Mantle cell lymphoma. Nui nō hoʻi nā hoʻokolohua lapaʻau mua me nā lāʻau lapaʻau hou e hōʻike ana i ka ʻōlelo hoʻohiki. ʻO ka hopohopo aʻe, ʻo ia me kēia mau lāʻau lapaʻau hou a me nā lāʻau lapaʻau hui pū, hiki mai ka hoʻonui kālā no nā ʻōnaehana olakino.
Prof Stephan Stilgenbauer a me Deborah Sims - Nā mea hou e pili ana i ka hoʻokele o CLL / SLL.
Ua hāʻawi ʻo Prof Stilgenbauer i kahi hiʻohiʻona o nā mea hou o ka mālama ʻana i nā maʻi me CLL / SLL mai ka hālāwai ASH. Kūkākūkā ʻo ia i ka hoʻohana ʻana i nā lāʻau lapaʻau hou ma ke ʻano he mau mea hoʻokahi a me nā hui pū ʻana e loaʻa ana nā hopena koʻikoʻi no nā poʻe maʻi, ʻoi aku ka poʻe i loaʻa i ka maʻi unmutated a no laila ʻaʻole pane i ka hoʻokele maʻamau e pili ana i ka chemotherapy. ʻO ka lāʻau lapaʻau i ka wā e hiki mai ana no CLL/SLL e lilo paha ka chemotherapy i ka lua a i ʻole ke kolu o ka lāʻau lapaʻau.
A/Prof Constantine Tam a me Deborah Sims - CLL & Mantle Cell Lymphoma.
Ua kamaʻilio ʻo A/Prof Constantine Tam, Peter MacCallum Cancer Center, RMH & St Vincent's Hospital iā Deborah Sims, mai Lymphoma Australia. Hāʻawi ʻo Dr Tam i kāna mau ʻike mai nā mea koʻikoʻi mai ka hālāwai ma CLL a me Mantle cell lymphoma. Ua hāʻawi ʻo ia i kahi hiʻohiʻona o kāna mau hōʻike 3 mahalo nui ʻia no Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL).
Ua hahai ʻo Dr George - nā mea hou CLL.
Ua kamaʻilio ʻo Dr George Follows mai UK me Lymphoma Australia ma ka hui ʻAmelika Hui Pū ʻIa o Hematology (ASH) i mālama ʻia ma Orlando, USA. ʻO Dr Follows ka Lymphoma/CLL Clinical Lead no Cambridge a paʻa pū ʻo ia i kekahi mau koho me ka noho o ka UK CLL forum. Ua kūkākūkā ʻo ia i nā mea hou e pili ana i ka noiʻi a me nā hopena noiʻi hou i hōʻike ʻia ma ka hālāwai ASH ma CLL.
ʻO Dr Nitin Jain lāua ʻo Deborah Sims - Ibrutinib & Venetoclax i nā maʻi me CLL.
ʻO Dr Nitan Jain he Kauka Hoʻohui i ka 'Oihana o Leukemia ma ke Kulanui o Texas MD Anderson Cancer Center ma Houston, Texas, USA. Ua kūkākūkā ʻo Dr Nitan i kāna mau hōʻikeʻike 2 i ka wā o ka hālāwai ASH o nā haʻawina 2 i mālama ʻia ma MD Anderson Cancer Center me ka hoʻohana ʻana i ka Ibrutinib a me ka venetoclax hui pū me nā maʻi me ka maʻi lymphocytic leukemia (CLL) ma ka lāʻau lapaʻau mua a me ka poʻe me ka maʻi relapsed / refractory. Ua hōʻike ʻia nā hopena ma nā pūʻulu ʻelua, ʻo ka hoʻohana ʻana i ka ibrutinib a me ka venetoclax ka lāʻau lapaʻau i hoʻohana ʻia i ka chemotherapy-free oral regimen no nā maʻi me CLL a e hoʻomau ʻia nā haʻawina hou.
Kauka Tanya Siddiqi - CAR T-cell i hoʻihoʻi ʻia / refractory CLL.
ʻO Dr Tanya Siddiqi ka Luna Hoʻokele, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center a me A/Prof Department of Hematology & Hematopoietic Transplantation ma ke kūlanakauhale ʻo Hope National Medical Center, Duarte, USA. Ua kūkākūkā ʻo Dr Siddiqi i kāna hōʻike ʻana i ka wā o ka hālāwai o ka pae aʻu e aʻo ai i ka mālama ʻana i nā mea maʻi relapsed a refractory me CLL. Ua loaʻa i nā maʻi āpau ma mua o 3 mau lāʻau lapaʻau maʻamau, me ka ibrutinib a me ka hapalua o nā maʻi i loaʻa i ka venetoclax. Ua mālama ʻia ka haʻawina i nā maʻi maʻi 23 me CAR T-cell therapy kahi i loaʻa ai ma luna o 80% nā pane lōʻihi ma mua o 6 mau mahina. Ke hoʻomau nei ka hahai ʻana.
Prof John Seymour - Nānā o ka haʻawina Murano - CLL/SLL.
Ua hōʻike ʻo Prof Seymour i ka loiloi makahiki ʻehā o ka noiʻi Murano e hōʻoia i ka pōmaikaʻi mau o ka manawa palena Venetoclax & rituximab i ka relapsed a refractory chronic lymphocytic leukemia (CLL). ʻO Venetoclax (Ven) kahi mea hoʻopaneʻe waha koho nui o ka mea hoʻoponopono apoptosis kī BCL-2, i hōʻike nui ʻia ma CLL. MURANO (kahi hoʻopaʻa haʻawina Phase III) i hoʻohālikelike ʻia ʻo VenR lōʻihi me ka bendamustine-rituximab (BR) maʻamau ma R/R CLL. Ua hoʻokumu ʻia ke ola holomua holomua ʻole (PFS) o VenR versus BR i ka loiloi mua i hoʻolālā ʻia (Seymour et al. N Engl J Med 2018); Ua ʻike ʻia ka pōmaikaʻi PFS me ka mālama lōʻihi a ma hope o ka pau ʻana o ka lāʻau lapaʻau.
Prof Peter Hillmen - Nā pilikia i ka ʻāina mālama CLL/SLL.
Kūkākūkā ʻo Prof Hillman i kekahi o nā paʻakikī o ka hoʻololi wikiwiki ʻana i ka ʻāina lapaʻau no CLL/SLL me nā lāʻau lapaʻau hou ma ka mākeke.
ʻO Prof Peter Hillmen - nā mea hou CLL mai ASH 2019.
Ua kūkākūkā ʻo Prof Hillmen i kekahi o nā mea koʻikoʻi loa mai ka hālāwai e pili ana i nā hoʻāʻo ʻana i ka novel therapy i hoʻohana ʻia ma ka pae mua i hōʻike ʻia e hōʻike ana i nā hopena maikaʻi me ka hoʻohana ʻana i ka ibrutinib (BTK inhibitor), acalabrutinib (he hanauna hou BTK inhibitor), venetoclax (BCL2 inhibitor). ) a me ka hoʻohana ʻana i nā lāʻau lapaʻau hui. Ua kūkākūkā pū ʻo ia i nā hoʻokolohua lapaʻau i ka hoʻonohonoho hoʻihoʻi hou ʻana e hōʻike ana i nā hopena maikaʻi i komo pū me CAR T-cell therapy. Mahalo iā Leukemia Care no ka haʻi ʻana i ka nīnauele me Lymphoma Australia.
Prof Miles Prince - Hoʻāʻo Genetic (CLL/SLL) & CAR T-cell therapy.
Ua kūkākūkā ʻo Prof Prince i kona mau manaʻo e pili ana i nā kumuhana hoihoi no ka lymphoma mai ka hālāwai. Ua kūkākūkā ʻo ia ʻo ke ala maikaʻi loa e mālama ai i ka lymphoma o ka mea maʻi, pono e hoʻomaopopo a ʻike piha ʻia kā lākou ʻike. Ua hōʻike ʻia ʻo nā maʻi i loaʻa i ka maʻi CLL/SLL pono e hoʻāʻo genetic ma mua o ka loaʻa ʻana o ka lāʻau lapaʻau. ʻO nā maʻi i hoʻololi ʻole ʻia a me kahi TP53 mutated CLL/SLL, ua hōʻike ʻia ʻaʻole maikaʻi ka chemotherapy no kēia hui maʻi. Ma USA a me UK (a me kekahi mau ʻāina ʻEulopa) ua loaʻa kālā ka poʻe maʻi e loaʻa iā Ibrutinib front-line, akā naʻe ʻaʻole kēia ka hihia ma Australia, kahi e loaʻa ai nā maʻi i ka chemo-immunotherapy a me ka ibrutinib i ka lāʻau lapaʻau lua.
ʻO Lymphoma B-cell nui (DLBCL)
ʻO A/Prof Chan Cheah - Lymphoma Kūʻē, Hoʻopuehu i nā lymphoma pūnaewele B nui.
Hoʻoponopono hou ʻo A/Prof Cheah i ka pepa "Aggressive Lymphoma (Diffuse Large B-cell and other aggressive b-cell non-Hodgkin lymphomas) - nā hopena mai nā hoʻokolohua lapaʻau e hiki mai ana: e hoʻonui ana i ka chemotherapy mua" i mālama ʻia ma ka lā 8 Dekemaba ma ASH 2019.
ʻO Dr Jason Westin - Hoʻolaha i nā mea hou Lymphoma B-cell nui a me ke aʻo hoʻomaka akamai.
Ua kūkākūkā ʻo Dr Westin i kekahi o nā mea koʻikoʻi mai ka hālāwai kūkā ma DLBCL me ka CAR T-cell therapy a me nā mea hou mai nā haʻawina e hoʻohana ana i ka chemotherapy liʻiliʻi a no laila e hoʻomaikaʻi ai i nā hopena ʻino no nā maʻi.
ʻO Follicular Lymphoma
ʻO Kauka Loretta Nastoupil - ke aʻo ʻana i ka lymphoma Follicular - Māhele 1.
Ke kūkākūkā nei ʻo Dr Nastoupil i nā hopena o kāna aʻo ʻana i ka pae II o Obintuzumab (type II anti-CD20 monoclonal antibody) a me Lenalidamide (immunomodulatory agent) i ka mālama ʻole ʻia, ke kaumaha nui o ka maʻi FL. ʻO kēia hui pū ʻana o nā lāʻau lapaʻau i ʻike ʻia e ʻae maikaʻi ʻia a maikaʻi hoʻi i kahi noiʻi mua no nā maʻi i mālama ʻia i ka relapsed a refractory FL.
ʻO Kauka Loretta Nastoupil - ke aʻo ʻana i ka lymphoma Follicular - Māhele 2.
Ua kūkākūkā ʻo Dr Nastoupil i nā hopena o kāna noiʻi ʻana i ka pae II o Obintuzumab (type II anti-CD20 monoclonal antibody) a me Lenalidamide (immunomodulatory agent) ma mua o ka mālama ʻole ʻia, ke kaumaha nui o ka maʻi FL. Pono ke aʻo hou aʻe o kēia ʻano hana hoʻomaʻamaʻa immune i ka FL i mālama ʻole ʻia. Kūkākūkā ʻo Dr Nastoupil i nā kumu o kēia ala kūpono a ʻae ʻia no kēlā me kēia heluna o nā maʻi me ka follicular lymphoma.
ʻO A/Prof Chan Cheah - Hoʻohou hoʻāʻo hoʻokolohua Follicular lymphoma.
Ua kūkākūkā ʻo Dr Cheah i kahi hōʻike i hāʻawi ʻia e Dr Loretta Nastoupil mai MD Anderson Cancer Center, Texas i ka wā o ka hālāwai ASH 2019. Ua nānā ka haʻawina ʻāpana II i ka mālama ʻana i nā poʻe maʻi Follicular lymphoma i mālama ʻole ʻia me Obintuzumab (type II anti-CD20 monoclonal antibody) a me Lenalidamide (immunomodulatory agent), me kahi kaumaha nui o ke koko. Ua ʻike ʻia kēia hui ʻana o nā lāʻau lapaʻau e ʻae maikaʻi ʻia a maikaʻi hoʻi i kahi noiʻi mua no nā maʻi i mālama ʻia i ka relapsed a refractory FL i mālama ʻia ma MD Anderson Cancer Center e Prof Nathan Fowler (RELEVANCE study).
ʻO Dr Allison Barraclough -Nivolumab + Rituximab ma ka laina mua Follicular Lymphoma.
Ua kūkākūkā ʻo Dr Barraclough i nā hopena manawa o ka haʻawina mua ma ka pae II honua, i alakaʻi ʻia e Dr Eliza Hawkes, ka hoʻokele mua o nā maʻi me ka pae 1-3A follicular lymphoma. Ke hoʻohana nei ka haʻawina i kahi hoʻohui immunotherapy wale nō, i hoʻāʻo ʻia ma mua i ka hoʻonohonoho hoʻihoʻi. Loaʻa i nā maʻi ka nivolumab wale nō no nā pule 8 mua a inā loaʻa iā lākou kahi pane piha, e hoʻomau ʻia me ka nivolumab agent hoʻokahi. No ka poʻe i loaʻa i kahi pane hapa wale nō e hele i ka hui pū ʻana ma nivolumab a me rituximab. Ua maikaʻi nā hopena me ka helu pane holoʻokoʻa (ORR) o 80% a ma luna o ka hapalua o kēia mau maʻi i loaʻa i kahi pane piha (CR). Loaʻa ka haʻahaʻa haʻahaʻa haʻahaʻa, kahi i hiki ai i nā mea maʻi ke hana a hoʻomau i nā hana ola maʻamau
ʻO Lymphoma Cell Mantle
ʻO Dr Sasanka Handunetti - Mantle Cell Lymphoma (Hoʻohou o ka haʻawina AIM).
Ua kūkākūkā ʻo Dr Handunetti i kāna hōʻike e pili ana i ka hoʻonui ʻana i ʻekolu mau makahiki o ke aʻo ʻana o ka pae II AIM (TAM, et al, NEJM 2018) i mālama ʻia ma Peter MacCallum Cancer Center ma Melbourne, me ka hoʻohana ʻana i ka BTK inhibitor ibrutinib a me BCL-2 inhibitor venetoclax therapy i nā maʻi me maikaʻi ʻole prognosis mantel cell lymphoma (MCL). Ua hōʻike ʻia nā hopena i ka piʻi ʻana o ke ola manuahi o 29 mau mahina. Ua hāpai ʻo ia i ka nīnau he hiki ke kaupalena ʻia ka manawa i hoʻopaʻa ʻia-agent therapy i ka mālama ʻana i ka MCL relapsed a refractory paha.
ʻO Prof Steven Le Gouill - ke aʻo ʻana o Mantle Cell Lymphoma.
Ua kūkākūkā ʻo Prof Le Gouill i kāna māhele aʻu e aʻo ai no ka MCL hou i ʻike ʻia me ka hoʻohana ʻana iā Ibrutinib, Venetoclax a me Obintuzumab i hōʻike mua ʻia i ka maikaʻi i ka hoʻonohonoho hou ʻana / refractory ma ke ʻano he mau mea hoʻokahi a i hui pū ʻia i ka relapsed / refractory (R/R) MCL. . Ua hāʻawi pū ʻo ia i kahi hiʻohiʻona o ka mālama maʻamau no nā maʻi me MCL no ka mea maʻi ʻōpio a me ka mea maʻi kahiko ma ka laina mua a me ka hoʻokele R / R.
ʻO Prof Simon Rule - Mantle Cell Lymphoma Update.
Ua kūkākūkā ʻo Prof Simon Rule i kāna hōʻike hoʻolaha ma ka hālāwai e nānā ana i ka 7.5 makahiki ka hahai ʻana o nā maʻi me ka relapsed a refractory MCL ka poʻe maʻi i ka ibrutinib (BTK inhibitor) i hōʻike i kahi helu nui o nā maʻi i ke kala ʻia ʻoi aku ma mua o 5 mau makahiki. Ua hōʻike pū ʻia ʻo ka poʻe maʻi i loaʻa iā Ibrutinib i nā lālani mua o ka lāʻau lapaʻau i ʻoi aku ka maikaʻi o ka pane lōʻihi, ma mua o ka poʻe i loaʻa ia lateistique.
KTE-X19: He koho T-Cell kaʻa no Mantle Cell Lymphoma?
He kanaiwakūmākolu pākēneka o nā maʻi me ka relapsed/refractory mantle cell lymphoma (MCL) i pane i ka mālama ʻana me KTE-X19, kahi autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, e like me nā hopena mai ka hoʻokolokolo ZUMA-2 i hōʻike ʻia. i ka 2019 ASH Annual Meeting.
Hodgkin Lymphoma
ʻO Kauka Jessica Hochberg - Chemotherapy, ʻOpio a me Hodgkin Lymphoma.
He kiʻekiʻe ka lāʻau lapaʻau no ka Hodgkin Lymphoma hou me ka hoʻohana ʻana i ka chemoradiotherapy. Eia naʻe, hopena pinepine kēia i ka hana kino kino a me ka psychosocial maikaʻi loa e hiki ke hoʻopilikia nui i ka maikaʻi o ke ola ma waena o nā mea ola. ʻO ka hoʻohui ʻana o Brentuximab vedotin a me Rituximab i ka hui ʻana i ka chemotherapy i hoʻohālikelike ʻia (me ka ʻole o ka cyclophosphamide, etoposide a i ʻole bleomycin) no ka Hodgkin Lymphoma hou i ʻike ʻia he palekana i nā keiki, nā ʻōpio a me nā ʻōpio. Hōʻike kā mākou mau hopena i ka ʻōlelo hoʻohiki nui me ka helu CR o 100%, 58% pane wikiwiki wikiwiki a me ka hōʻemi nui ʻana i ka hoʻohana ʻana i ka chemotherapy a me ka radiation. ʻO ka EFS / OS a hiki i kēia lā ʻo 100% me kahi manawa hahai ma waena o ka nui o 3.5 mau makahiki.
Prof Andrew Evens - HoLISTIC Hodgkin Lymphoma International Study.
He lālā ikaika ʻo Prof Evens o ka HoLISTIC (Hodgkin Lymphoma International Study for Individual Care) - he consortium honua e hui pū ana i kahi hui o nā loea like ʻole mai ka honua holoʻokoʻa e aʻo i nā ʻano koʻikoʻi o Hodgkin lymphoma prognosis, epidemiology, mālama, ola a me nā hopena olakino. ma waena o nā hui makahiki āpau. Ke hoʻohālikelike nei lākou i ka ʻikepili maʻi maʻi mai ka ʻoi aku o 20 mau hoʻokolohua lapaʻau o kēia manawa mai ʻAmelika ʻAmelika a me ʻEulopa o nā makahiki āpau a me 6 mau hoʻopaʻa inoa ʻo Hodgkin lymphoma, a me kahi hana oncology kaiaulu nui. ʻO kā lākou pahuhopu ka hoʻoikaika ʻana i ka hoʻoholo ʻana no nā maʻi lymphoma pediatric a me nā mākua Hodgkin lymphoma, hāʻawi ʻia i ka hoʻonui ʻana i nā koho lapaʻau a me ka loaʻa ʻole o ka ʻikepili prognostic acute a lōʻihi.
ʻO Kauka Stephen Ansell lāua ʻo Deborah Sims - Hodgkin Lymphoma.
He loea koʻikoʻi ʻo Dr Ansell ma non-Hodgkin lymphoma a me Hodgkin lymphoma ma ka Mayo Clinic, USA. Ua kamaʻilio ʻo Dr Ansell e pili ana i ka lymphoma Hodgkin - ke kau mua o ka lāʻau lapaʻau ma ASH āna i hele ai. Hōʻike ka hālāwai i kahi hoʻokolohua lapaʻau kahi i hoʻohana hou ʻia ai i nā lāʻau lapaʻau hou i ka hoʻonohonoho mua, kahi e hoʻohui ai iā Brentuximab Vedotin & a PD-1 inhibitor a hōʻemi i kekahi o ka chemotherapy maʻamau i bleomycin, hōʻike i nā hopena koʻikoʻi. Ua hōʻemi pū nā hopena i ka ʻawaʻawa no nā poʻe maʻi e loaʻa ana i kēia lapaʻau i ka hoʻohālikelike ʻana i ka lāʻau maʻamau. He kiʻekiʻe ka lāʻau lapaʻau maʻamau ma Hodgkin lymphoma ma luna o nā pane pane āpau ma kahi o 90% o ka mea maʻi i hiki i kahi pane metabolic piha. Nui nā hoʻāʻo ʻana ma Hodgkin lymphoma i kēia manawa e hoʻemi i ka ʻike ʻona a me nā hopena hope loa no kēia mau maʻi.
ʻO Lymphoma ʻĀpana Marginal
ʻO Kauka Sasanka Handunetti - Ke aʻo ʻana i ka Phase II i ka Lymphoma Marginal Zone Relapsed a Refractory paha.
Ua kūkākūkā ʻo Dr Handunetti i kahi hōʻike pepa mai ka hui ma Peter MacCallum Cancer Center i ka wā o ka hālāwai o ka hoʻohana ʻana i ka ibrutinib i hui pū me ka venetoclax no nā maʻi me ka relapsed a refractory Marginal Zone Lymphoma (MZL). He maʻi hiki ʻole ke hoʻōla ʻia ka MZL ʻaʻohe maʻamau o ka mālama mālama ʻana i ka hoʻihoʻi ʻana a i ʻole ka refractory. Ua ʻike ʻia kēia mau lāʻau ʻelua i nā hōʻike o ka hana a me ka ʻae ʻana ma ke ʻano he monotherapies (mau mea hoʻokahi) a ua manaʻo kēia noiʻi e loiloi i ka pane ʻana ma ke ʻano he lāʻau hoʻohui.
Lymphoma Pūnaehana Nervous Central
ʻO Kauka Katherine Lewis - Lymphoma Pūnaehana Nervous Central (PCNSL).
Ua kūkākūkā ʻo Dr Lewis i kahi hōʻike hoʻolaha ma ASH 2019 e nānā ana i nā hopena no nā mea maʻi me ka lymphoma mua a i ʻole ke kula waena (lolo a me ka spine) lymphoma i mālama ʻia me Ibrutinib (BTK inhibitor). He lymphoma kakaʻikahi kēia a me ka huhū kahi i loaʻa ai i kēia pūʻulu maʻi kahi wānana maikaʻi ʻole me ka mālama pinepine ʻana me nā regimens chemotherapy. He haʻawina retrospective kēia i hōʻiliʻili i ka ʻike mai nā ʻaoʻao o Australia a me New Zealand o 16 mau maʻi i mālama ʻia me ka monotherapy Ibrutinib i ka hoʻonohonoho hoʻihoʻi / refractory. ʻOiai he helu liʻiliʻi o nā maʻi, ua hoʻohiki nā hopena, me nā pane pane a hiki i 81%.
ʻO ka Macroglobulinemia o Waldenstrom
ʻO Prof Mathias Rummel - Waldenstrom's Macroglobulinemia & ka hoʻokolokolo StiL.
Uhi i nā hualoaʻa makahiki 2 ma hope o ke aʻo ʻana o StiL e nānā ana i ka mālama ʻana iā Rituximab vs observation post bendamustine-rituximab. Hōʻike nā hopena i ka mālama ʻana i ka rituximab ʻaʻole e hoʻomaikaʻi i ke ola holoʻokoʻa. Hāʻawi pū ʻo Prof Rummel i kahi ʻike o ka hoʻokele o WM i kēia manawa.
T-cell Lymphoma
ʻO Lymphoma T-cell puni
ʻO Dr Jasmine Zain, MD - kūkākūkā i nā haʻawina hoihoi loa ma PTCL i hōʻike ʻia ma ASH 2019.
(Mahalo iā OBRoncology).
ʻO Dr. Zain, Luna Hoʻokele o ka T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, e kūkākūkā ana i nā haʻawina hoihoi loa i ka mālama ʻana i ka peripheral T-cell lymphoma (PTCL) i hōʻike ʻia ma ASH 2019.
ʻO Dr Jasmine Zain - Pehea ka ulu ʻana o ka mālama ʻana i ka lymphoma T-cell peripheral.
(Mahalo iā OBRoncology).
Noʻonoʻo ʻo Dr. Zain, Luna Hoʻokele o ka T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, e noʻonoʻo ana i ka ulu ʻana o ka lāʻau T-cell lymphoma (PCL) i nā makahiki i hala.
ʻO Dr Jasmine Zain - Ke hoʻokokoke nei ka Novel e mālama i ka PTCL me ka CAR T-cell therapy.
(Mahalo iā OBRoncology).
ʻO Kauka Zain, Luna Hoʻokele o ka T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, e haʻi mai iā mākou e pili ana i kekahi o nā ala hou i ka hoʻomohala ʻana no ka mālama ʻana i ka lymphoma T-cell peripheral ( PTCL).
ʻO Dr Timothy Illidge, wehewehe i ke kumu o ka huli ʻana i ka PTCL.
(Mahalo iā OBRoncology).
Ua wehewehe ʻo Kauka Illidge, Polofesa o Targeted Therapy and Oncology, Division of Cancer Science, The Christie Hospital, University of Manchester, i ke kumu o ka huli ʻana i ka peripheral t-cell lymphoma (PTCL).
